Skip to search formSkip to main contentSkip to account menu

monoclonal antibody 2021

Known as: concizumab, mAb 2021 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
Results from the main parts (24 weeks) of two concizumab phase 2 trials are presented: explorer4 (NCT03196284) in hemophilia A… 
2019
2019
Concizumab enhances thrombin generation (TG) potential in haemophilia patients by inhibiting tissue factor pathway inhibitor… 
2018
2018
Essentials explorer™3 was a double‐blinded, multiple‐dose escalation trial of subcutaneous concizumab. A pharmacodynamic… 
Review
2018
Review
2018
Replacement therapy with missing factor (F) VIII or IX in haemophilia patients for bleed management and preventative treatment or… 
Highly Cited
2017
Highly Cited
2017
Concizumab, a humanized monoclonal antibody against tissue factor pathway inhibitor (TFPI), is being developed as a… 
2016
2016
The development of inhibitors to factor VIII (FVIII) or factor IX (FIX) remains a major treatment complication encountered in the… 
Highly Cited
2015
Highly Cited
2015
Prophylaxis with either intravenous (i.v.) factor VIII (FVIII) or FIX is the gold standard of care for patients with severe… 
Review
2015
Review
2015
  • P. Monahan
  • Hematology. American Society of Hematology…
  • 2015
  • Corpus ID: 24887563
For more than 3 decades, the scientific community has pursued gene correction of hemophilia, with the goal that an individual…